Skip to main content
. 2022 Sep 8;8:88. doi: 10.1038/s41421-022-00455-6

Fig. 6. Inhibition of SARS-CoV-2 infection by S-20-1 that specifically targets at RBD and HR1 domain at the early stage of viral entry.

Fig. 6

a In PsV infection assay, Huh-7 cells were pretreated with S-20-1 at 50 µM at 37 oC for 1 h, washed with PBS to remove unbound S-20-1, and infected with SARS-CoV-2 at 37 oC. In time-of-addition assays, Huh-7 and RD cells were treated with S-20-1 at the indicated time points before or after addition of pseudotyped SARS-CoV-2 (b) and authentic HCoV-OC43 (d), respectively. Supernatants containing free S-20-1 and viral particles were removed 12 h later. A series of well-established assays were performed to confirm the stage at which S-20-1 blocked entry of SARS-CoV-2 or HCoV-OC43 into target cells. Data were analyzed with One-way ANOVA (a) and Two-way ANOVA (c, e). NS means no significance. Affinity of binding between S-20 and S1 (f), S-20-1 and S1 (g), S-20 and RBD (h), S-20-1 and RBD (i), S-20 and HR1 (j), or S-20-1 and HR1 (k), was determined by fluorescence polarization.